Channel therapeutics corp CHRO.US 總覽分析
CHRO 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
公司發布財報數據季度不足，尚無法提供評分
CHRO 近期報酬表現
0.80%
Channel therapeutics corp
3.56%
同產業平均
1.47%
S&P500
與 CHRO 同產業的標的表現
- SLRX Salarius pharmaceuticals inc價值 3 分趨勢 2 分波段 2 分籌碼 -股利 1 分查看更多
CHRO 公司資訊
Channel Therapeutics Corporation is engaged in developing innovative, non-addictive, drugs to treat chronic neuropathic and acute and chronic eye pain. The Company is focused on the development of non-opioid pain treatment therapeutics with a focus on modulating NaV1.7 receptors responsible for sensing and transmitting pain in the peripheral nervous system. It is initially targeting orphan chronic pain indications, specifically small fiber neuropathy and erythromelalgia, and acute and chronic eye pain. The Company's patented, selective, and potent (nM) inhibitor of human NaV1.7 has demonstrated additional efficacy in several models of pain: acute, chronic, inflammatory, visceral, post-surgical, and chemotherapy-induced.